Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + Platinum-based Chemotherapy in Advanced NSCLC
NCT01160744Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2010
- Primary completion
- Jan 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of ramucirumab in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Sep 2010; status: completed.
02
Drugs
ramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01160744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01160744.